Sunshine Biopharma Inc. (SBFM) - 10-K Summary
Business Context and Reporting Period
Reporting Period: Fiscal year ended December 31, 2024.
Company Overview: Sunshine Biopharma Inc. operates as a pharmaceutical company with two primary business segments: (1) Commercial sales of generic prescription drugs in Canada through its wholly-owned subsidiary, Nora Pharma Inc., and (2) Proprietary drug development for oncology (K1.1 mRNA) and antivirals (SBFM-PL4). The company also sells over-the-counter (OTC) supplements.
Market Position: As of December 31, 2024, Nora Pharma marketed 70 generic prescription drugs in Canada, with 64 additional drugs in the pipeline. The company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $34,874,283 | $24,092,787 |
| Cost of Sales | $24,204,489 (69.4%) | $15,753,616 (65.4%) |
| Gross Profit | $10,669,794 | $8,339,171 |
| Net Loss | $(5,134,116) | $(4,506,044) |
| Cash and Equivalents (Year-End) | $9,686,529 | $16,292,347 |
| Total Assets | $30,560,392 | $27,346,961 |
| Total Liabilities | $7,059,638 | $6,139,600 |
| Accumulated Deficit | $(69,039,774) | $(63,905,658) |
Liquidity: The company reported a net cash outflow from operating activities of $12.5 million in 2024, primarily due to increased inventory and expansion of operations. Financing activities provided $9.3 million, driven by a public offering and warrant exercises. Management believes existing cash is sufficient to fund operations for the next 24 months.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased by approximately 45% ($10.8 million) compared to 2023. This was driven by the expansion of sales efforts into Ontario, Alberta, and British Columbia, and the addition of 5 new products to the portfolio.
- Margin Compression: Gross margin decreased from 34.6% in 2023 to 30.6% in 2024. The increase in Cost of Sales (69.4% of revenue) was attributed to higher professional allowances incurred on sales outside Quebec, where allowances are government-capped.
- Operating Expenses: General and Administrative (G&A) expenses rose by $3.4 million to $16.5 million, reflecting the expansion of sales operations and increased salaries.
- Inventory Build-up: Inventory nearly doubled from $5.7 million in 2023 to $11.3 million in 2024 to support expanded sales.
- Goodwill Impairment: The company recorded a full impairment of $18.3 million in goodwill related to the Nora Pharma acquisition in 2022, resulting in a $0 goodwill balance as of December 31, 2024.
Guidance, Outlook, and Risks
Outlook: Management anticipates launching 13 additional generic drugs in 2025. The company expects to require additional funding for future R&D, clinical trials, and generic operations expansion. No dividends are anticipated in the foreseeable future.
Key Risks and Contingencies:
- Profitability: The company has an accumulated deficit of ~$69 million and may never achieve profitability.
- Regulatory & Supply Chain: Reliance on third-party manufacturers outside North America exposes the company to supply chain disruptions. Pricing in Canada is subject to government negotiations (pCPA).
- Listing Status: The company faced delisting proceedings by Nasdaq in 2024 due to low bid price and warrant structure concerns. While compliance was regained in September 2024, the company is under a one-year Mandatory Panel Monitor. Failure to maintain compliance could result in delisting.
- R&D Uncertainty: Proprietary drug candidates (K1.1 and SBFM-PL4) are in animal testing stages. There is no assurance they will receive regulatory approval or generate revenue.
- Accountant Change: The company dismissed its previous auditor, BF Borgers CPA, PC, following an SEC settlement and permanent ban. Bush & Associates CPA LLC was retained in May 2024.
Investor Verification Checklist
- Cash Runway: Verify if the $9.7 million cash balance is sufficient to cover the projected $12.5 million annual operating burn rate plus R&D costs for the stated 24-month period.
- Nasdaq Compliance: Monitor the company's stock price and warrant structure to ensure it remains compliant with Nasdaq listing rules during the one-year monitoring period.
- Inventory Valuation: Assess the $11.3 million inventory balance for potential obsolescence risks, given the competitive nature of the generic drug market and pricing pressures.
- Executive Compensation: Review the amended employment agreement with CEO Dr. Steve N. Slilaty, which includes a potential severance payment of $14 million upon termination without cause.
- Goodwill Impairment: Understand the rationale for the full goodwill impairment and its impact on future financial reporting and asset valuation.